Gilead Sciences, Inc. (BIT:1GILD)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 136.96 billion. The enterprise value is 149.24 billion.

Market Cap	136.96B
Enterprise Value	149.24B

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 12, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	87.84%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.81 and the forward PE ratio is 15.03.

PE Ratio	19.81
Forward PE	15.03
PS Ratio	5.52
PB Ratio	7.49
P/TBV Ratio	n/a
P/FCF Ratio	17.54
P/OCF Ratio	16.62
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.21, with an EV/FCF ratio of 19.11.

EV / Earnings	21.59
EV / Sales	6.00
EV / EBITDA	12.21
EV / EBIT	15.35
EV / FCF	19.11

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 24.42%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	24.42%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	1.41M
Profits Per Employee	392,736
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 1.51 billion in taxes.

Income Tax	1.51B
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +20.54% in the last 52 weeks. The beta is 0.35, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	+20.54%
50-Day Moving Average	105.73
200-Day Moving Average	98.82
Relative Strength Index (RSI)	58.03
Average Volume (20 Days)	213

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.39

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 24.79 billion and earned 6.91 billion in profits. Earnings per share was 5.47.

Revenue	24.79B
Gross Profit	19.51B
Operating Income	9.69B
Pretax Income	8.43B
Net Income	6.91B
EBITDA	12.05B
EBIT	9.69B
Earnings Per Share (EPS)	5.47

Balance Sheet

The company has 7.24 billion in cash and 21.26 billion in debt, with a net cash position of -12.31 billion.

Cash & Cash Equivalents	7.24B
Total Debt	21.26B
Net Cash	-12.31B
Net Cash Per Share	n/a
Equity (Book Value)	18.29B
Book Value Per Share	14.78
Working Capital	4.75B

Cash Flow

In the last 12 months, operating cash flow was 8.24 billion and capital expenditures -430.41 million, giving a free cash flow of 7.81 billion.

Operating Cash Flow	8.24B
Capital Expenditures	-430.41M
Free Cash Flow	7.81B
FCF Per Share	n/a

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 2.76, which amounts to a dividend yield of 2.59%.

Dividend Per Share	2.76
Dividend Yield	2.59%
Dividend Growth (YoY)	-3.19%
Years of Dividend Growth	n/a
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	1.57%
Earnings Yield	5.05%
FCF Yield	5.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7